Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease (NCT04925375)
🩺 Plain-English Summary (8th-Grade Level)
There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID. This study is a multi-site, phase II, randomized, blinded/placebo-controlled clinical trial in pediatric and adult subjects to determine the efficacy of abatacept compared to placebo for treatment of subjects with GLILD in the context of CVID. Funding Source - FDA OOPD
Who can join: Review the eligibility criteria below.
Location: University of California, San Francisco — San Francisco, California
Age range: 4 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- University of California, San Francisco — San Francisco, California
- University of South Florida — Tampa, Florida
- Lahey Hospital and Medical Center — Burlington, Massachusetts
- Mayo Clinic — Rochester, Minnesota
- Duke University Health System — Durham, North Carolina
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
📞 Contact the Study Coordinator
Phone: (513) 803-9063
Email: Michael.Jordan.@cchmc.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Interstitial Lung Disease
- Genentech Validation Tool for Pulmonary Fibrosis — New York, New York
- FAPI PET for Lung Fibrosis — Los Angeles, California
- Interstitial Lung Disease Research Unit Biobank — Kansas City, Kansas
- Hyperpolarized 129Xe MRI for Imaging Pulmonary Function — Durham, North Carolina
- Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough — Rochester, Minnesota
- Pulmonary Hypertension SOLAR — Durham, North Carolina
Explore by condition: All Interstitial Lung Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.